Aliment Pharmacol Ther 29(2):198206
The strongest evidence-based case for GLP-1 therapy is in patients who have both overweight or obesity and established cardiovascular disease
But it proved that activating the GLP-1 pathway could work as a real therapy
Red flag symptoms requiring urgent medical attention include: Severe, persistent abdominal pain , particularly in the upper abdomen or epigastric region, which could indicate pancreatitis (a rare but serious adverse effect of GLP-1 therapy) Difficulty swallowing (dysphagia) or painful swallowing (odynophagia) Unintentional weight loss beyond expected therapeutic effects Persistent vomiting that prevents adequate oral intake or medication administration Right upper quadrant pain, fever, or yellowing of skin/eyes , which could indicate gallbladder disease (a known risk with weight loss on GLP-1 therapies) Symptoms of gastroparesis such as early satiety, postprandial fullness, or vomiting undigested food Call 911 or seek emergency care immediately for: Severe chest pain that could represent cardiac pathology rather than reflux Evidence of gastrointestinal bleeding , including black, tarry stools or vomiting blood or coffee-ground material If you suspect pancreatitis (persistent severe abdominal pain, sometimes radiating to the back, with or without nausea/vomiting), stop taking the GLP-1 medication immediately and seek urgent medical care, as directed in FDA prescribing information
All authors approved the version to be published
